Published in Blood Weekly, October 19th, 1998
Treatment options for patients with myelodysplastic syndrome (MDS) are limited; allogeneic bone marrow transplantation (BMT) is the only proven curative therapy. While 30 percent to 50 percent of MDS patients who receive BMT experience long-term, event-free survival (EFS), relapse of disease and nonrelapse mortality (NRM) are significant.
To identify prognostic factors that influence outcome in this patient population, Thomas J. Nevill, Vancouver Hospital and Health Sciences Centre,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.